Health Condition 1: I998- Other disorder of circulatory system
Conditions
Interventions
Intervention1: TABLET.DAPAGLIFLOZIN 10 MG OD: TABLET DAPAGLIFLOZIN 10 MG ONCE A DAY IS GIVEN TO PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION FOR THREE MONTHS AND FOLLOWED UP REGUARLY O
Sponsors
srm university
Eligibility
Inclusion criteria
Inclusion criteria: MALE AND FEMALE CONSENTING TO PARTICIPATE IN THE STUDY LEFT VENTICULAR EJECTION FRACTION MORE THAN 50 % PATIENTS WITH INCRASED N TERMINAL PRO BRAIN NATRIURETIC PEPTIDE MORE THAN 300 PG KNOWN TYPE II DIABETES MILLETUS PATIENT NOT ON SODIUM GLUCOSE CO TRANSPORTER II THERAPY
Exclusion criteria
Exclusion criteria: PATIENT NOT CONSENTING TO PARTICIPATE IN STUDY CHRONIC KIDNEY DISEASE WITH ESTIMATED GLOMERULAR FILTRATION RATE OF LESS THAN 20 ML PER MINUTE CHRONIC OBSTRUCTIVE PULMONARY DISEASE CHRONIC LUNG DISEASE PATIENTS WITH MYOCARDIAL INFARCTION CORONARY ARTERY BY PASS GRAFT CARDIOMYOPATHIES VALVULAR HEART DISEASE CURRENT OR PRIOR USE OF SODIUM GLUCOSE CO TRANSPORETER II INHIBITORS
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IMPROVEMENT OF EJECTION FRACTION OF PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION PATIENT INITIATED ON TABLET DAPAGLIFLOZIN 10MG ONCE A DAY AND REVIEWED AFTER THREE MONTHS OF INITIATION OF THERAPY AND CLINICAL IMPROVEMENT IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTIONTimepoint: Follow up of patients with heart failure with preserved ejection fraction with echocardiography on initial zero visit and follow up at Three months and n terminal pro brain natriuretic peptide at initial visit at o day and followed up for improvement at second visit at three months | — |
Secondary
| Measure | Time frame |
|---|---|
| CLINICAL IMPROVEMENT IN KCCQ SCORETimepoint: 2 WEEKS | — |
Countries
India
Contacts
Public ContactDr Saurav P Singhvi
srm medical college hospital and research centre
Outcome results
None listed